October 13, 2005 -- Johnson & Johnson alleges that Amgen is engaging in anti-trust activity, forcing oncology clinics to sign exclusive contracts for Aranesp iinstead of Procrit, Array BioPharma and Genentech will extend their cancer collaboration (again), Access Pharma sold its oral care business to Uluru in a deal worth up to $20.6 million, Inspire Pharma reported on three cystic fibrosis safety studies, and Chiron received FDA permission to begin distributing the first lots of its flu vaccine. Biotech was strong today, with the Centient Biotech 200 climbing 45 points to close at 3624, a rise of 1.27%. More details...
